Clik here to view.
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2022 third quarter results and latest corporate...
View ArticleClik here to view.
麒麟控股与花王联合研究内脏脂肪与免疫学的关系
东京 (美国商业资讯)–麒麟控股株式会社（Kirin Holdings Company, Limited，简称“麒麟控股”）和花王株式会社（Kao Corporation，简称“花王”）将从本月起参加由和歌山县立医科大学牵头、由非营利组织健康促进研究中心(HPRC)编制的“和歌山健康促进研究”队列研究*1。麒麟控股和花王将联合开展研究，探究内脏脂肪与免疫系统的主要群体之一浆细胞样树突状细胞*2...
View ArticleClik here to view.
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy...
View ArticleClik here to view.
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in...
OXFORD, England & HOUSTON, Texas Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric...
View ArticleClik here to view.
GICELL Announces the Preclinical Research Data Demonstrating the Superiority...
SEONGNAM, South Korea GICELL announced the data from the preclinical studies on T.O.P. NK (Tumor targeting, Optimally Primed NK), an allogeneic NK cell therapy which had been presented at the...
View ArticleClik here to view.
TMD LAB Collaborates With US NIST to Reveal the Secrets of Shape-memory...
SEOUL, South Korea TMD LAB (CEO Hak-Joon Sung) and the National Institute of Standards and Technology (NIST) under the U.S. Department of Commerce are starting joint research on the properties of...
View ArticleClik here to view.
BeiGene Launches Talk About It Program to Elevate the Importance of...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It:...
View ArticleClik here to view.
Exscientia和MD安德森启动战略合作，利用人工智能开发新型肿瘤疗法
英格兰牛津和得克萨斯州休斯敦 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)和得克萨斯大学MD安德森癌症中心今天宣布达成了一项战略合作，将Exscientia以患者为中心的人工智能(AI)能力与MD安德森的药物发现和开发专长相结合，以推进新型小分子肿瘤疗法。...
View ArticleClik here to view.
Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring...
MONTREAL Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial...
View ArticleClik here to view.
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
PHCグループ 中期経営計画 「Value Creation Plan」を改定－「バリューベース・ヘルスケア」の実現に貢献し成長を加速
東京 （ビジネスワイヤ） — PHCホールディングス株式会社（本社: 東京都港区、代表取締役社長CEO：宮﨑 正次、以下「PHCグループ」) は、このたび、PHCグループの中期経営計画「Value Creation Plan」(*1)を改定しましたので、お知らせいたします。PHCグループは、以下に示す３つの成長領域においてバリューベース・ヘルスケアへ貢献することで、更なる成長を目指します。...
View ArticleClik here to view.
PHC Group Releases Newly Revised Mid-Term Plan, the “Value Creation Plan,”...
TOKYO PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: Shoji Miyazaki, hereafter PHC Group) announces the release of its newly revised Mid-term Plan, the “Value...
View ArticleClik here to view.
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3...
DUBLIN Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed enrollment of its Phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA for the treatment of active...
View ArticleClik here to view.
Genome Insight and Kun-hee Lee Child Cancer ＆ Rare Disease Project Team of...
SAN DIEGO Genome Insight, a precision medicine whole genome platform company, and Kun-hee Lee Child Cancer & Rare Disease Project Team of SNUH (Seoul National University Hospital), funded by the...
View ArticleClik here to view.
SNU Bundang Hospital and Cipherome, Inc. conclude an MOU for cooperation in...
SAN JOSE, Calif. Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinico genomic research...
View ArticleClik here to view.
HIROTSU BIO SCIENCE INC.: World’s First Test for Early-Stage Pancreatic...
TOKYO HIROTSU BIO SCIENCE INC. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu; hereafter referred to as “HIROTSU”) is pleased to announce the commercialization of “N-NOSE plus...
View ArticleClik here to view.
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib)...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has...
View ArticleClik here to view.
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed...
OSAKA, Japan & CAMBRIDGE, Mass Takeda (TSE:4502/NYSE:TAK) today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with...
View ArticleClik here to view.
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of...
HOUSTON ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has...
View ArticleClik here to view.
The New England Journal of Medicine and NEJM Group partner with Wolters...
WALTHAM, Mass. Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM...
View Article